|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Tau protein is found to be aggregated and hyperphosphorylated (p-tau) in many neurologic disorders, including Parkinson disease (PD) and related parkinsonisms, Alzheimer disease, traumatic brain injury, and even in normal aging.
|
31085590 |
2019 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
MAPT-AS1, a long non-coding RNA (lncRNA) existing at the anti-sense strand of the MAPT (microtubule associated protein tau) promoter region, was believed to regulate MAPT, which was associated with disease state in Parkinson's disease.
|
30074401 |
2019 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that H1/H2 MAPT haplotype is not a risk factor to PD in our population.
|
30339920 |
2019 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
We uncover many novel genes associated with PD but also novel mechanisms for known associations such as MAPT, for which we find that variation in exon 3 splicing explains the common genetic association.
|
30824768 |
2019 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
AD is characterized by deposition of extracellular beta-amyloid (Aβ) proteins and intracellular neurofibrillary tangles (NFT), composed of hyperphosphorylated tau proteins in the neurons located particularly in hippocampus and cerebral cortex regions of brain, resulting the neuronal loss, while PD is characterized by deposition of intraneuronal aggregates of mostly composed of alpha-synuclein gene as Lewy bodies (LB) in the striatal region, known as substantia nigra pars compacta (SNpc) of brain, leading to the death of dopaminergic neurons.
|
30877973 |
2019 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The cytoplasmic microtubule associated protein tau and alpha-synuclein (αS) are found in an assembled state in Alzheimer's disease and Parkinson's disease, respectively.
|
31214163 |
2019 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The MAPT H1 haplotype has been identified as a predictor of cognitive decline in Parkinson's disease (PD).
|
29899731 |
2018 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder.
|
29756641 |
2018 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aggregation of NFTs, the abnormal hyperphosphorylation of tau protein, and the interaction between tau and alpha-synuclein may all contribute to the cell death and poor axonal transport observed in PD and Parkinsonism.
|
30333786 |
2018 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease.
|
29669022 |
2018 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Five members (two symptomatic patients and three patients with a presymptomatic mutation) from the FTDP-17 pedigree were enrolled, in comparison with 9 patients with Parkinson disease (PD) and 11 control patients.
|
30353822 |
2018 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pooled-DNA target sequencing of 7 major PD genes (SNCA, PARK2, PINK1, DJ-1, LRRK2, GBA, and MAPT) was performed in 562 PD cases.
|
29887346 |
2018 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We assessed possible RBD (pRBD) status using the RBD screening questionnaire and investigated known susceptibility variants for Parkinson's disease located in the α-synuclein (SNCA) and tau (MAPT) gene loci in 325 Parkinson's disease patients.
|
29466944 |
2018 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hyperphosphorylated tau protein is a key pathology in Alzheimer's disease (AD), frontotemporal dementia, chronic traumatic encephalopathy, and Parkinson's disease.
|
29914030 |
2018 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have analyzed NMS burden assessed through an extensive clinical and neuropsychological battery in 137 consecutive non-demented PD patients genotyped for MAPT haplotypes (H1/H1 vs H2 carriers) in order to explore the applicability of the "anatomo-clinical", "motor" or "genetic" models for subtyping PD in a clinical setting; a subsequent independent analysis was conducted to verify a possible cluster distribution of NMS.
|
29627019 |
2018 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition to the MAPT H1 haplotype, we identified a variant near the chemokine receptor CXCR4 that was jointly associated with increased risk for PSP and PD.
|
29636460 |
2018 |
|
Parkinson Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of amyloid and tau-proteins correlate with cognitive decline and may have prognostic value for cognitive deficits in PD.
|
26991855 |
2017 |
|
Parkinson Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This work links haplotype-specific MAPT expression with a biologically functional outcome relevant for PD.
|
28689993 |
2017 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Advances in genetics have identified PD-associated mutations and variants in genes encoding various proteins affecting microtubule function including the microtubule-associated protein tau.
|
27600680 |
2017 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms.
|
28257128 |
2017 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We observed SNPs within the HLA, MAPT and APOE regions jointly contributing to increased risk for FTD and AD or PD.
|
27899424 |
2017 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genome wide association studies have identified microtubule associated protein tau (MAPT) H1 haplotype single nucleotide polymorphisms (SNPs) as leading common risk variants for Parkinson's disease, progressive supranuclear palsy and corticobasal degeneration.
|
29084565 |
2017 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study demonstrated that different variants in MAPT were associated with AD (rs2471738: OR= 1.04, 95%CI = 1.00 - 1.09; H2: OR = 0.94, 95% CI = 0.91 - 0.97), PD (H2: OR = 0.76, 95% CI = 0.74 - 0.79), PSP (rs242557: OR = 1.96, 95% CI = 1.71 - 2.25; rs2471738: OR = 1.85, 95% CI = 1.
|
28402959 |
2017 |
|
Parkinson Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD).
|
28839167 |
2017 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Abnormally phosphorylated tau protein is the key common marker in several brain diseases such as Alzheimer's disease, Parkinson`s disease, Pick Disease, Down syndrome and frontotemporal dementia and is capable of affecting synaptic events that are critical for memory formation.
|
27539594 |
2017 |